Skip to main content
Toggle navigation
Search
Home
Dermatology
Home
Dermatology
Dermatology
Type here to filter the list
(95) Bridging the beauty gap: evaluating access barriers to aesthetic dermatology in underserved populations through a managed care lens
(96) Navigating Specialty Treatment for Dermatologic Inflammatory Conditions: Patient Journey and Treatment Persistence
(97) A cost per responder analysis of ritlecitinib and baricitinib: assessing the impact of clinical efficacy and dosing variability on overall treatment costs of severe alopecia areata
(98) Real-world treatment patterns in patients with psoriasis receiving tildrakizumab compared to ustekinumab
(99) Long-term efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: 3-year results from the ALLEGRO-LT phase 3, open-label study
(100) The Economic Impact of Ustekinumab in the Treatment of Psoriasis: A Targeted Literature Review
(101) Improvement in atopic dermatitis signs and symptoms with once-daily and proactive twice-weekly roflumilast cream 0.15% or 0.05%: results from the 52-week phase 3 INTEGUMENT-OLE trial in patients aged ≥2 years
(102) Caregiver-reported outcomes from the phase 3 INTEGUMENT-PED trial of children aged 2–5 years with atopic dermatitis and treated with roflumilast cream 0.05%
(103) Efficacy and safety of roflumilast foam 0.3% in patients with psoriasis of the scalp and body in the phase 3 ARRECTOR trial
(104) Prevalence and advanced systemic treatment prescription patterns for scalp psoriasis in the real-world dermatology setting in the United States
(105) Economic burden of moderate-to-severe chronic hand eczema in the United States: A retrospective claims analysis
(106) Budget impact analysis of tralokinumab-ldrm for moderate-to-severe atopic dermatitis in the United States
(107) Real-world effect of ruxolitinib cream: decreased use of additional topical therapies and limited escalation to systemic treatments
(108) Examining the Shifts in Atopic Dermatitis: A Retrospective Study of Patient Demographics and Insurance Coverage from 2018 to 2023
